CN107108646A - 阿根诺卡菌素类化合物及其作为抗菌剂的用途 - Google Patents

阿根诺卡菌素类化合物及其作为抗菌剂的用途 Download PDF

Info

Publication number
CN107108646A
CN107108646A CN201580069971.4A CN201580069971A CN107108646A CN 107108646 A CN107108646 A CN 107108646A CN 201580069971 A CN201580069971 A CN 201580069971A CN 107108646 A CN107108646 A CN 107108646A
Authority
CN
China
Prior art keywords
alkyl
substituent
arya
heta
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580069971.4A
Other languages
English (en)
Chinese (zh)
Inventor
K.扬
D.B.奥尔森
S.B.辛格
J.苏
R.R.维尔克宁
J.M.阿普加尔
D.蒙
D.帕克
M.曼达尔
L.杨
R.E.派因特
Q.当
T.铃木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CN107108646A publication Critical patent/CN107108646A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580069971.4A 2014-10-22 2015-10-21 阿根诺卡菌素类化合物及其作为抗菌剂的用途 Pending CN107108646A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/089204 2014-10-22
PCT/CN2014/089204 WO2016061772A1 (en) 2014-10-22 2014-10-22 Nargenicin compounds and uses thereof as antibacterial agents
PCT/US2015/056627 WO2016064982A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Publications (1)

Publication Number Publication Date
CN107108646A true CN107108646A (zh) 2017-08-29

Family

ID=55760063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580069971.4A Pending CN107108646A (zh) 2014-10-22 2015-10-21 阿根诺卡菌素类化合物及其作为抗菌剂的用途

Country Status (11)

Country Link
US (2) US9944654B2 (https=)
EP (1) EP3209667B1 (https=)
JP (1) JP2017533200A (https=)
KR (1) KR20170070197A (https=)
CN (1) CN107108646A (https=)
AU (1) AU2015335992A1 (https=)
BR (1) BR112017008101A2 (https=)
CA (1) CA2964377A1 (https=)
MX (1) MX2017005271A (https=)
RU (1) RU2017117253A (https=)
WO (2) WO2016061772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
KR102440647B1 (ko) 2020-07-28 2022-09-06 선문대학교 산학협력단 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148883A (en) 1977-08-18 1979-04-10 Pfizer Inc. Antibiotics produced by new species of nocardia
US4351769A (en) * 1980-08-25 1982-09-28 The Upjohn Company Antibiotic composition of matter
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives
US4436747A (en) 1982-10-21 1984-03-13 Pfizer Inc. Nargenicin C1
ES2258234T3 (es) 2002-08-12 2006-08-16 PHARMACIA & UPJOHN COMPANY LLC N-aril-2-oxazolidinonas y sus derivados.
GB0227701D0 (en) 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
MXPA05005522A (es) 2002-11-28 2005-07-25 Astrazeneca Ab Oxazolidinonas como agentes antibacterianos.
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
JP2008500318A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
WO2007133803A2 (en) 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
KR101040468B1 (ko) 2008-02-29 2011-06-09 조선대학교산학협력단 새로운 노카르디아 속 균주 및 그의 발효 배양물의 용도
KR101022564B1 (ko) 2008-12-19 2011-03-16 조선대학교산학협력단 나르제니신을 포함하는 염증성 신경퇴행성 질환의 치료용 제약 조성물
WO2011139832A2 (en) 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARNEY J MAGERLEIN，等: "9-O-ESTERS OF NODUSMICIN", 《THE JOURNAL OF ANTIBIOTICS》 *

Also Published As

Publication number Publication date
KR20170070197A (ko) 2017-06-21
EP3209667A1 (en) 2017-08-30
CA2964377A1 (en) 2016-04-28
RU2017117253A (ru) 2018-11-23
EP3209667A4 (en) 2018-06-06
JP2017533200A (ja) 2017-11-09
RU2017117253A3 (https=) 2019-04-16
AU2015335992A1 (en) 2017-04-20
US10144741B2 (en) 2018-12-04
WO2016064982A1 (en) 2016-04-28
EP3209667B1 (en) 2025-03-19
US9944654B2 (en) 2018-04-17
WO2016061772A1 (en) 2016-04-28
MX2017005271A (es) 2017-08-15
US20180186808A1 (en) 2018-07-05
BR112017008101A2 (pt) 2018-02-20
US20170305924A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
CN108778273B (zh) 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法
CN109071504A (zh) 受体相互作用蛋白激酶1的抑制剂
JP2020536082A (ja) 細菌感染症を治療するためのクロマンモノバクタム化合物
CN112469725A (zh) 青霉素结合蛋白抑制剂
KR102611447B1 (ko) 박테리아 감염을 치료하는 화합물 및 방법
JP5142730B2 (ja) 抗感染薬としての新規なイソチアゾロキノロンおよび関連化合物
US10144741B2 (en) Nargenicin compounds and uses thereof as antibacterial agents
CA3145555C (en) Compounds and methods of use thereof as antibacterial agents
WO2018175185A1 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
CN111527093B (zh) 抗菌杂环化合物及其合成
RU2794494C2 (ru) Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств
HK40047984A (en) Penicillin-binding protein inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170829

RJ01 Rejection of invention patent application after publication